Vaxcyte (PCVX) Receivables - Other (2020 - 2025)

Vaxcyte (PCVX) has 6 years of Receivables - Other data on file, last reported at $21.4 million in Q4 2025.

• Receivables - Other for Q4 2025 came in at $21.4 million, up 5.4% year-over-year; the trailing twelve-month figure through Dec 2025 was $21.4 million (up 5.4% YoY), and the FY2025 annual result was $21.4 million, up 5.4% from the prior year.
• Receivables - Other rose to $21.4 million in Q4 2025 per PCVX's latest filing, from $20.3 million in the prior quarter.
• Over five years, Receivables - Other peaked at $21.4 million in Q4 2025 and troughed at $700000.0 in Q2 2021.
• A 5-year average of $8.8 million and a median of $5.8 million in 2023 frame the typical range for Receivables - Other.
• The sharpest annual moves came in 2024 and 2025: Receivables - Other soared 463.15% in 2024, then advanced 5.4% in 2025.
• A 5-year view of Receivables - Other shows it stood at $700000.0 in 2021, then jumped by 306.86% to $2.8 million in 2022, then gained by 26.33% to $3.6 million in 2023, then soared by 463.15% to $20.3 million in 2024, then increased by 5.4% to $21.4 million in 2025.
• Business Quant data shows PCVX's Receivables - Other at $21.4 million in Q4 2025, $20.3 million in Q4 2024, and $17.6 million in Q3 2024.